drugset / Trial / NCT00006441
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
Completed
398 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Agouron Pharmaceuticals · collabChiron Corporation · collabGlaxo Wellcome · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period that immediately follows infection with HIV). After primary HIV infection, the actual infection is spread through an increasing amount of HIV virus in the body. Studies have shown that, by taking a combination of anti-HIV drugs, it is possible to reduce the amount of HIV in the body to almost undetectable levels. This study will find out if starting anti-HIV drugs during primary infection will interrupt or reduce the spread of HIV in patients' bodies.
Timeline
- Start
- 2003-02
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 7.5 iu | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Nelfinavir | Other / unclassified | 1250 mg | — |
| Background | Stavudine | Other / unclassified | 40 mg | — |
| Background | Zidovudine | Small molecule | 150 mg | — |